Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
| Autor: | Simone Edenhofer, Stephan Stilgenbauer, Sven Estenfelder, Henriette Huber |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty Chronic lymphocytic leukemia BCL-2 Context (language use) Review 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Chemoimmunotherapy Internal medicine hemic and lymphatic diseases medicine Pharmacology (medical) TP53 venetoclax Venetoclax business.industry medicine.disease Fludarabine Regimen chemistry 030220 oncology & carcinogenesis del(17p) Rituximab Refractory Chronic Lymphocytic Leukemia business CLL 030215 immunology medicine.drug |
| Zdroj: | OncoTargets and therapy |
| ISSN: | 1178-6930 |
| Popis: | Over the last few years, dramatic changes have occurred in the treatment of chronic lymphocytic leukemia (CLL). The current standard for young and fit patients with CLL remains chemoimmunotherapy, namely the fludarabine, cyclophosphamide, and rituximab (FCR) regimen. However, novel oral therapies are presently being introduced and represent a considerable breakthrough concerning effectiveness and safety profile. In particular, the very high-risk group of CLL patients, defined by the genetic aberration del(17p) and/or TP53 mutation, benefit from the new agents. These genetic abnormalities are the most relevant negative prognostic markers in the context of chemoimmunotherapy. New targeted therapies allow different approaches to improve outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|